The European Tribune is a forum for thoughtful dialogue of European and international issues. You are invited to post comments and your own articles.
Please REGISTER to post.
No wonder most of the Brit press is crowing about victory is this new Battle of Britain and sees their perceived upmanship as an opportunity to improve Brexit to the UK's advantage. What is there to negotiate now? Haven't we been there before?
We still have no clear or convincing explanation as to why AstraZeneca won't deliver doses from its UK facilities to the EU, in addition to the Belgium and NL ones, as allowed for in the contract.
We only know that Astra is UK headquartered and that the price paid by the UK government is higher than the one negotiated by the EU. In a tight supply situation, it makes perfect business sense to allocate your deliveries to the highest prices markets first (a similar situation does exist in the chip industry - I did work in that sector some years ago).
Again, all the above is just speculation at this point, and we'll probably not get any explanation for a long time, if we ever get one.
Your 2021-2026 UK-EU trade war scenario is looking eerily prescient.
Yep, that is a crucial bit of missing information. Also, are there any penalties for non-delivery in the contract?
And does EU have any equivalent to the US War Production Act to set aside the Oxford/AztraZeneca patent rights and let production companies churn out generica as soon as possible?
By happenstance I found out that Finland is using doses made in Sweden (in Södertälje to be precise).
AstraZeneca says it will boost vaccine production to 2M a week | Politico - Jan. 15, 2021 | Health authorities in the UK have decided to change their distribution strategy, prioritizing giving as many people a first shot as possible. British drugmaker AstraZeneca says it will boost production of the coronavirus vaccine it developed with Oxford University to two million doses a week by the middle of January. According to the Times, an unnamed member of the Oxford/AstraZeneca team said production was expected to reach a total of 1 million doses by the end of next week. "The plan is then to build it up fairly rapidly -- by the third week of January we should get to two million a week," they added. ... Meanwhile, a senior scientist from Oxford University has complained that the country's pharmaceutical manufacturing base is not prepared to handle the roll-out of the jab. "The government has been completely disinterested in building onshore manufacturing capacity for any of the life-sciences products," said John Bell, professor of medicine at Oxford.
Health authorities in the UK have decided to change their distribution strategy, prioritizing giving as many people a first shot as possible.
British drugmaker AstraZeneca says it will boost production of the coronavirus vaccine it developed with Oxford University to two million doses a week by the middle of January.
According to the Times, an unnamed member of the Oxford/AstraZeneca team said production was expected to reach a total of 1 million doses by the end of next week.
"The plan is then to build it up fairly rapidly -- by the third week of January we should get to two million a week," they added.
...
Meanwhile, a senior scientist from Oxford University has complained that the country's pharmaceutical manufacturing base is not prepared to handle the roll-out of the jab.
"The government has been completely disinterested in building onshore manufacturing capacity for any of the life-sciences products," said John Bell, professor of medicine at Oxford.
Simple math ... manufacturing rate of 52 million per year to double to 104 million 🚱 ... cutting corners to please the Brexiteers in the City.
Update on the vaccine supply issues & confusing govt lines on this 1/2 @ks_1968 [_link]— Sarah Rosemary (@SarahRosemary3) January 2, 2021
Update on the vaccine supply issues & confusing govt lines on this 1/2 @ks_1968 [_link]
Contrary to popular belief, congress deliberately constrained powers granted to a POTUS to contract and order supplies for, ahem, national defense in several ways--including but not limited to the Fund balance and "foreign entities"-- so as to limit liabilities and test impairment of the "domestic industrial base". Besides which, the cost of "nationalizing" private property effectively deters seizures as well unilateral prerogative, which appeared to be the case for Youngstown Sheet & Tube Co..
By and large, the act provides for mundane appropriations to fill recurring DoD contract tenders.
by Luis de Sousa - Feb 28 1 comment
by IdiotSavant - Feb 28
by Oui - Mar 1 1 comment
by Frank Schnittger - Feb 23 15 comments
by Oui - Feb 22 19 comments
by Oui - Feb 25
by Frank Schnittger - Feb 20 16 comments
by gmoke - Feb 14 2 comments
by Oui - Mar 11 comment
by gmoke - Mar 1
by Luis de Sousa - Feb 281 comment
by Oui - Feb 2827 comments
by Frank Schnittger - Feb 2315 comments
by Oui - Feb 2219 comments
by Frank Schnittger - Feb 2016 comments
by Oui - Feb 2021 comments
by Frank Schnittger - Feb 1914 comments
by Oui - Feb 197 comments
by Oui - Feb 18
by Oui - Feb 1787 comments
by Oui - Feb 168 comments
by Frank Schnittger - Feb 1523 comments
by gmoke - Feb 142 comments
by Frank Schnittger - Feb 1413 comments
by Oui - Feb 145 comments
by Oui - Feb 1245 comments